Physician profile
Jonathan Adelson
NPI 1700864501
$5,432.56
in general payments reported to CMS, 2019-2025
37 companies · $1,531 in 2025
The $1,531 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,637 · 2020: $70.04 · 2021: $30.42 · 2022: $262 · 2023: $493 · 2024: $1,410 · 2025: $1,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,353 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,353.49 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $907.90 | 2019-2025 | Krystexxa, Tavneos, Otezla |
| Janssen Biotech, INC. | $842.67 | 2019-2025 | Tremfya |
| Abbvie INC. | $650.95 | 2019-2025 | Qulipta, Rinvoq, Humira |
| Glaxosmithkline, LLC. | $340.00 | 2019-2025 | Benlysta |
| Pfizer INC. | $332.45 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $258.54 | 2019-2025 | Orencia |
| Ucb, INC. | $257.54 | 2022-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $251.55 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $193.71 | 2023-2025 | Saphnelo, Flumist Quadrivalent |
| Mallinckrodt Hospital Products INC. | $191.85 | 2025 | Acthar |
| Novo Nordisk INC | $129.44 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Aurinia Pharma U.S., INC. | $84.69 | 2022-2025 | Lupkynis |
| Genzyme Corporation | $84.34 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $83.02 | 2025 | Purified Cortrophin Gel |
| Pacira Pharmaceuticals Incorporated | $77.42 | 2024-2025 | Zilretta, Iovera |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $71.88 | 2024 | Hyrimoz |
| Mallinckrodt Enterprises LLC | $56.70 | 2019 | |
| Alexion Pharmaceuticals, INC. | $55.83 | 2024 | Strensiq, Ultomiris |
| Hikma Pharmaceuticals USA | $49.05 | 2019 | |
| Sobi, INC | $48.30 | 2019-2025 | |
| Radius Health, INC. | $47.66 | 2024 | Tymlos |
| Genentech USA, INC. | $42.26 | 2019-2025 | Actemra, Ocrevus Zunovo |
| Merck Sharp & Dohme LLC | $41.88 | 2019 | |
| Lilly USA, LLC | $41.82 | 2019-2024 | Zepbound |
| Scilex Pharmaceuticals INC. | $40.82 | 2024 | |
| Invivyd INC | $37.76 | 2025 | Pemgarda |
| Horizon Therapeutics Plc | $30.62 | 2019-2022 | |
| Pacira Therapeutics, INC. | $28.88 | 2019 | |
| Saluda Medical Americas, INC. | $23.75 | 2025 | Evoke |
| Zimmer Biomet Holdings, INC. | $20.84 | 2019 | |
| Fresenius Kabi USA, LLC | $19.67 | 2023 | Idacio |
| Sanofi Pasteur INC. | $17.87 | 2019 | |
| Tonix Medicines, INC. | $17.40 | 2025 | Tonmya |
| Celgene Corporation | $16.70 | 2019 | |
| Assertio Therapeutics, INC. | $13.37 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $11.73 | 2019 | |
| Depuy Synthes Sales INC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Adelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.